Advanced search
Publication Cover
Personalized Medicine Volume 3, 2006 - Issue 2
Submit an article Journal homepage
204
Views
0
CrossRef citations to date
0
Altmetric
Review

Past, Present and Future of Gene Expression-Tailored Therapy for Lung Cancer

Estelle Marrer1 Novartis AG, Basel, Switzerland. estelle.marrer/jeanne.kehren/[email protected]
,
Florent Baty2 University Hospital Basel, Pulmonary Gene Research, Basel, Switzerland. batyf/[email protected]
,
Jeanne Kehren1 Novartis AG, Basel, Switzerland. estelle.marrer/jeanne.kehren/[email protected]
,
Salah-Dine Chibout1 Novartis AG, Basel, Switzerland. estelle.marrer/jeanne.kehren/[email protected]
&
Martin Brutsche2 University Hospital Basel, Pulmonary Gene Research, Basel, Switzerland. batyf/[email protected]
Pages 165-175 | Published online: 05 May 2006

Bibliography

  • American C ancer Society:Cancer facts and figures 2005. American Cancer Society, Atlanta, GA, USA (2005).
  • Schiller JH, Harrington D, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer.N. Engl. J. Med.346(2), 92–98 [Clinical Trial] (2002).
  • Klastersky J , PaesmansM: Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results.Lung Cancer34(Suppl. 4), 95–101 (2001).
  • Meyerson M , CarboneD: Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy.J. Clin. Oncol.23(14), 3219–3226 (2005).
  • Mariani TJ , KaminskiN: Gene expression studies in lung development and lung stem cell biology.Curr. Top. Dev. Biol.64, 57–71 (2004).
  • Tonon G , WongKK, MaulikG et al.: High-resolution genomic profiles of human lung cancer.Proc. Natl Acad. Sci. USA102(27), 9625–9630 (2005).
  • Li H , LuanY: Kernel Cox regression models for linking gene expression profiles to censored survival data.Pac. Symp. Biocomput.,65–76 (2003).
  • Danesi R , de BraudF, FogliS et al.: Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.Pharmacol. Rev.55, 57–103 (2003).
  • Bild AH , YaoG, ChangJT et al.: Oncogenic pathway signatures in human cancers as a guide to targeted therapies.Nature439(7074), 353–357 (2005).
  • Sweet-Cordero A , MukherjeeS, SubramanianA et al.: An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.Nature Genet.37, 48–55 (2005).
  • Muller-Tidow C , MetzgerR, KuglerK et al.: Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.Cancer Res.61(2), 647–653 (2001).
  • Powell CA , SpiraA, DertiA et al.: Gene expression in lung adenocarcinomas of smokers and nonsmokers.Am. J. Respir. Cell. Mol. Biol.29(2), 157–162 (2003).
  • Fukumoto S i, Yamauchi N, Moriguchi H et al.: Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers’ non-small cell lung carcinomas.Clin. Cancer Res.11(5), 1776–1785 (2005).
  • Ji P , DiederichsS, WangW et al.: MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer.Oncogene22(39), 8031–8041 (2003).
  • Muller-Tidow C , DiederichsS, ThomasM, ServeH: Genome-wide screening for prognosis-predicting genes in early-stage non-small cell lung cancer.Lung Cancer45(Suppl. 2), 145–150 (2005).
  • Beer DG , KardiaSLR, HuangCC et al.: Gene-expression profiles predict survival of patients with lung adenocarcinoma.Nature Med.8(8), 816–824 (2002).
  • Rom WN , Tchou-WongKM: Functional genomics in lung cancer and biomarker detection.Am. J. Respir. Cell Mol. Biol.29(2), 153–156. (2003).
  • Ramaswamy S , RossKN, LanderES, Golub TR:A molecular signature of metastasis in primary solid tumors.Nature Genet.33, 49–54 (2003).
  • Tomida S , KoshikawaK, YatabeY et al.: Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients.Oncogene23(31), 5360–5370 (2004).
  • De Luca A , PignataS, CasamassimiA et al.: Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay.Clin. Cancer Res.6(4), 1439–1444 (2000).
  • Mao L : Recent advances in the molecular diagnosis of lung cancer.Oncogene21(45), 6960–6969 (2002).
  • Kopreski MS , BenkoFA, GockeCD: Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum.Ann. NY Acad. Sci.945, 172–178 (2001).
  • Hortobagyi GN : Trastuzumab in the treatment of breast cancer.N. Engl. J. Med.353(16), 1734–1736 (2005).
  • Sato JD , KawamotoT, LeAD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.Mol. Biol. Med.1(5), 511–529 (1983).
  • Dowsett M , BartlettJ, EllisIO et al.: Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.J. Pathol.199(4), 418–423 (2003).
  • Bartlett JMS : Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy.Am. J. Pharmacogenomics5(5), 303–315 (2005).
  • Hynes NE , LaneHA: ERBB receptors and cancer: the complexity of targeted inhibitors.Nature Rev. Cancer5, 341–354 (2005).
  • Wakeling AE , GuySP, WoodburnJR et al.: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.Cancer Res.62(20), 5749–5754 (2002).
  • Nicholson RI , GeeJM, HarperME: EGFR and cancer prognosis.Eur. J. Cancer37(Suppl. 4), 9–15 (2001).
  • Kosaka T , YatabeY, EndohH, KuwanoH, TakahashiT, MitsudomiT: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.Cancer Res.64(24), 8919–8923 (2004).
  • Lynch TJ , BellDW, SordellaR et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib.N. Engl. J. Med.350(21), 2129–2139 (2004).
  • Tomizawa Y , IijimaH, SunagaN et al.: Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.Clin. Cancer Res.11(19 Pt 1), 6816–6822 (2005).
  • Jain A , TindellCA, LauxI et al.: Epithelial membrane protein-1 is a biomarker of gefitinib resistance.Proc. Natl Acad. Sci. USA102(33), 11858–11863 (2005).
  • Tsai C -A, Wang S-J, Chen D-T, Chen JJ: Sample size for gene expression microarray experiments.Bioinformatics21, 1502–1508 (2005).
  • Li SS , BiglerJ, LampeJW, PotterJD, Feng Z: Controlling FDR and sample size determination for microarrays.Stat. Med.24, 2267–2280 (2005).
  • Ornstein DK , GillespieJW, PaweletzCP et al.: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines.Electrophoresis21(11), 2235–2242 (2000).
  • Repsilber D , ZieglerA: Two-color microarray experiments. Technology and sources of variance.Methods Inf. Med.44(3), 400–404 (2005).
  • Neuschafer D , BudachW, WankeC, ChiboutSD: Evanescent resonator chips: a universal platform with superior sensitivity for fluorescence-based microarrays.Biosens. Bioelectron.18(4), 489–497 (2003).
  • Hoffmann R , SeidlT, DugasM: Profound effect of normalization on detection of differentially expressed genes in oligonucleotide microarray data analysis.Genome Biol.3(7), RESEARCH0033 (2002).
  • Irizarry RA , HobbsB, CollinF et al.: Exploration, normalization, and summaries of high density oligonucleotide array probe level data.Biostatistics4(2), 249–264 (2003).
  • Bolstad BM , IrizarryRA, AstrandM, Speed TP:A comparison of normalization methods for high density oligonucleotide array data based on variance and bias.Bioinformatics19(2), 185–193 (2003).
  • Yang P , SunZ, AubryMC et al.: Study design considerations in clinical outcome research of lung cancer using microarray analysis.Lung Cancer46(2), 215–226 (2004).
  • Eisen MB , SpellmanPT, BrownPO, BotsteinD: Cluster analysis and display of genome-wide expression patterns.Proc. Natl Acad. Sci. USA95(25), 14863–14868 (1998).
  • Alaiya AA , FranzenB, HagmanA et al.: Classification of human ovarian tumors using multivariate data analysis of polypeptide expression patterns.Int. J. Cancer86(5), 731–736 (2000).
  • Fellenberg K , HauserNC, BrorsB, NeutznerA, HoheiselJD, VingronM: Correspondence analysis applied to microarray data.Proc. Natl Acad. Sci. USA98(19), 10781–10786 (2001).
  • Furey T , CristianiniN, DuffyN, Bednarski D, Schummer M, Haussler D: Support vector machine classification and validation of cancer tissue samples using microarray expression data.Bioinformatics16(10), 906–914 (2000).
  • Tibshirani R , HastieT, NarasimhanB, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression.Proc. Natl Acad. Sci. USA99(10), 6567–72 (2002).
  • Musumarra G , BarresiV, CondorelliDF, FortunaCG, ScireS: Genome-based identification of diagnostic molecular markers for human lung carcinomas by PLS-DA.Comput. Biol. Chem.29(3, 83–195 (2005).
  • Culhane AC , PerrièreG, ConsidineEC, CotterTG, HigginsDG: Between-group analysis of microarray data.Bioinformatics18(12), 1600–1608 (2002).
  • Suzuki R , ShimodeiraH: An application of multiscale bootstrap resampling to hierarchical clustering of microarray data: how accurate are these clusters?In Genome Informatics 2004 (2004).
  • Granville CA , DennisPA: An overview of lung cancer genomics and proteomics.Am. J. Respir. Cell Mol. Biol.32(3), 169–176 (2005).
  • Borczuk AC , GorensteinL, WalterKL, AssaadAA, WangL, PowellCA: Non-small cell lung cancer molecular signatures recapitulate lung developmental pathways.Am. J. Pathol.163(5), 1949–1960 (2003).
  • Garber ME , TroyanskayaOG, SchluensK et al.: Diversity of gene expression in adenocarcinoma of the lung.Proc. Natl Acad. Sci. USA98(24), 13784–13789 (2001).
  • Bhattacharjee A , RichardsWG, StauntonJ et al.: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.Proc. Natl Acad. Sci. USA98(24), 13790–13795 (2001).
  • Talbot SG , EstiloC, MaghamiE et al.: Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung.Cancer Res.65(8), 3063–3071 (2005).
  • Virtanen C , IshikawaY, HonjohD et al.: Integrated classification of lung tumors and cell lines by expression profiling.Proc. Natl Acad. Sci. USA99(19), 12357–12362 (2002).
  • Creighton C , HanashS, BeerD: Gene expression patterns define pathways correlated with loss of differentiation in lung adenocarcinomas.FEBS Lett.540(1–3), 167–170 (2003).
  • Wang H , ZhangZ, LiR et al.: Overexpression of S100A2 protein as a prognostic marker for patients with stage I non-small cell lung cancer.Int. J. Cancer116(2), 285–290 (2005).
  • Nguyen DV , RockeDM: Multi-class cancer classification via partial least squares with gene expression profiles.Bioinformatics18(9), 1216–1226 (2002).
  • Yee YJ , MangasarianOL, WolbergWH: Survival-time of breast cancer patients. Tech. rep., Department of Computer Science & Information Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan (2001).
  • Ntzani EE , IoannidisJPA: Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment.Lancet362(9394), 1439–1444 (2003).
  • Ein-Dor L , KelaI, GetzG, GivolD, DomanyE: Outcome signature genes in breast cancer: is there a unique set?Bioinformatics21(2), 171–178 (2005).
  • Michiels S , KoscielnyS, HillC: Prediction of cancer outcome with microarrays: a multiple random validation strategy.Lancet365(9458), 488–492 (2005).
  • Carr KM , RosenblattK, PetricoinEF, Liotta LA: Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.Hum. Genomics1(2), 134–140 (2004).
  • Irizarry RA , WarrenD, SpencerF et al.: Multiple-laboratory comparison of microarray platforms.Nature Methods2(5), 345–350 (2005).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.